Strides Pharma to invest $15m in Stelis’ $100m Series B round

Photo: Reuters

Strides Pharma Science Ltd on Thursday announced that its board has approved an investment of $15 million in Stelis Biopharma Pvt Ltd (Stelis), as part of the latter’s $100-million Series B funding round.

The first close of the current fundraise is $35 million, of which Strides will commit $15 million and $20 million is from other existing shareholders, Strides said, in a BSE announcement.

With the first close of Series B, Stelis has raised an equity capital of $114 million with Strides’ total investment at $37 million, granting it an effective ownership of 38 per cent. Strides currently owns 36.25 per cent stake in Stelis, the former biopharma division of the Indian drugmaker.

Strides had sold its 25.1 per cent stake in Stelis, formerly called Strides Shasun Ltd, to Jordan-based investment firm GMS Holdings for $21.9 million in 2014. GMS is said to have participated in the latest round.

Headquartered in Bengaluru, Stelis is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities from biological drug substance to aseptic fill-finish in various injectable formats.

It houses two facilities in Bengaluru including a state-of-the-art R&D and clinical-scale GMP facility and a 200,000 square feet bio-manufacturing campus for commercial manufacturing of recombinant bio-therapeutics.

Stelis has completed the construction of its biopharma manufacturing facility at Bengaluru, which is expected to go commercial for manufacturing and high-end CDMO services in the Q4 FY19. Two of the company’s key products are SBL001 and SBL005, which are for meant for osteoporosis and osteoarthritis therapeutic purposes, respectively.

The Indian pharmaceuticals sector has been abuzz with deal activities since past few months.

Mumbai-based online pharmacy startup PharmEasy had in September raised $50 million in a Series C round of funding led by Eight Roads Ventures India. The same month, Chennai-based online pharmacy firm Netmeds had raised $35 million from Singapore-based business conglomerate Daun Penh Cambodia Group. Existing investors Sistema Asia Fund and Cambodian investment firm Tanncam also took part in the round.

In July, Corner Store Technologies, that operates subscription pharmacy brand LifCare, raised $11 million in a Series B round of funding from private equity and venture capital firm SAIF Partners, Nexus Ventures and IL&FS.

Also Read:

Enam Securities, Arpwood to pick stake in Apollo’s pharmacy spinoff

India: Sun Pharma to acquire 18.75% stake in Israel’s Tarsius for $3m

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.